Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging

Radiology. 1994 Jun;191(3):625-31. doi: 10.1148/radiology.191.3.8184038.

Abstract

Purpose: To determine the accuracy of contrast material-enhanced subtraction dynamic magnetic resonance (MR) imaging in the diagnosis of nonpalpable breast tumors.

Materials and methods: One hundred forty-three patients underwent surgical biopsy of a nonpalpable breast lesion. Their mammograms showed microcalcifications (n = 80), opacity (n = 52), architectural distortion (n = 10), or asymmetric density (n = 1). All patients underwent a preoperative gadolinium tetraazacyclododecanetetraacetic acid-enhanced subtraction dynamic study. Any early contrast enhancement in the breast parenchyma was considered pathologic.

Results: At histologic analysis, 27 intraductal carcinomas, 37 invasive carcinomas, and 79 benign lesions were found. Dynamic MR studies showed early contrast enhancement in 61 of 64 breast cancers (sensitivity, 95%) and in 37 of 79 benign lesions (specificity, 53%). Two invasive lobular carcinomas and one tubular carcinoma showed no early contrast enhancement.

Conclusion: Subtraction dynamic MR imaging may be helpful to rule out malignancy in nonpalpable breast tumors.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / diagnosis*
  • Contrast Media*
  • Female
  • Heterocyclic Compounds*
  • Humans
  • Magnetic Resonance Imaging*
  • Mammography
  • Middle Aged
  • Observer Variation
  • Organometallic Compounds*
  • Palpation
  • Predictive Value of Tests
  • Prospective Studies
  • Sensitivity and Specificity
  • Subtraction Technique*

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate